BioTech Medics, Inc. Explores Patented SHBAN Solution As Potential Avian Bird Flu Water Prophylactic Additive at Poultry Farms
Posted on: Tuesday, 14 August 2007, 12:21 CDT
BioTech Medics, Inc. (PINKSHEETS: BTME) announced today that research has commenced exploring the possibility of BioTech's Patented SHBAN(TM) Solution being used as a safe non-toxic prophylactic water additive in poultry farms. The product could be available this fall if testing is successful.
SHBAN has been clinically tested at the University of London, Queens School of Medicine, Retroscreen Labs in London and proven to kill the HSN1 Influenza NIBRG-14 Virus. The Avian Bird Flu virus is transmitted by fowl via mucus and feces. SHBAN Solution is very effective in killing Avian Bird Flu on fowl feces and is non-toxic when used as directed (unlike ammonia based disinfectants).
The SHBAN(TM) solution, in previous in vitro and in vivo testing has been evaluated for its antimicrobial properties against S. Aureus, S. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Tests revealed that SHBAN was extremely effective against all species of bacteria that were tested. SHBAN has previously been tested by Baylor Medical Center in Houston, Louisiana State University, UT Houston, Allergan, Pathology Associates, MBA Labs and Texas A&M College of Veterinary Medicine. SHBAN is protected under US Letters of Patent #5,514.808, #5,574,050, #5,679,711 and #5,585,391. BioTech Medics will provide SHBAN samples to government or world health officials should they desire to independently test the SHBAN solution.
BioTech currently sells the "SHBAN 3 oz. Go Anywhere Hand Sanitizer Spray Mist." SHBAN is superior to alcohol hand sanitizers as it is long lasting by spraying a microscopic odorless, colorless non-toxic film on your hands which lasts until it is rubbed or washed off.
BioTech Medics is a 21st Century Alternative Medicine company. BioTech has Pain Management & Wellness Centers which feature the high powered NeuroLase Therapeutic Medical Laser, FDA cleared to reduce or eliminate muscular, skeletal or arthritic pain without drugs or surgery.
Safe Harbor for Forward-Looking Statements.
This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. The FDA has not made an evaluation of SHBAN or statements regarding SHBAN. SHBAN is not sold as a diagnosis, treatment or cure for any disease.
Contact: BTME Investor Relations 1-800-200-2458
SOURCE: BioTech Medics, Inc.
Source: MARKET WIRE
Related Articles
- CLX Medical, Inc. Announces Completion of Due Diligence and Sets Expected Timeline for Acquisition of Additional Medical Diagnostic Testing Product
- CLX Medical, Inc. Releases June 2008 Issue of Investor Newsletter Reviewing Current Status of Validation Study for Chlamydia Test and Proposed Acquisition of Additional Medical Diagnostic Testing Product
- CLX Medical, Inc. Announces Letter of Intent for Acquisition of Additional Medical Diagnostic Testing Product
- CLX Medical, Inc. Releases April 2008 Newsletter Highlighting New Corporate Name and Targeted Acquisition in the Medical Diagnostic Testing Market
- Upstream's Trypanosomiasis Drug Candidates Found to Be Safe in Toxicity Tests
- Upstream Biosciences' Novel Agents to Treat Leishmaniasis Demonstrate Promising Safety Profile in Initial Toxicity Testing
- Hartindo AF31 Aquatic Toxicity Test Results Announced
- Megola Initiates Aquatic Toxicity Testing for Hartindo AF31
- The Mount Sinai Medical Center and Reproductive Medicine Associates of New York Partner in Bringing Fertility Services to Queens
- Neuralstem Scientist Sees Stem Cell Technology Replacing Animal Toxicity Testing in Many Drug and Chemical Products
 |
 |
User Comments (0)
RSS Feeds